Stockreport

Conatus Pharmaceuticals’ Pan-caspase Inhibitor Emricasan Improves Survival and Portal Hypertension in a Mouse Model of Cirrhosis

CONATUS PHARMACEUTICALS INC  (CNAT) 
Last conatus pharmaceuticals inc earnings: 11/5 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.conatuspharma.com/investor-relations
PDF SAN DIEGO, July 02, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced the publication1 of results from preclinical studies of its pan [Read more]